Latest news
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo has entered into a feasibility…
Iconovo Accelerator Program
On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…
Press releases
Apr 28, 2021, 08:35
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 27, 2021, 09:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Apr 27, 2021, 09:30
News
IR
English
Corporate Information
Other Corporate Information
Apr 21, 2021, 13:15
News
IR
English
Corporate Information
Other Corporate Information
Apr 21, 2021, 13:15
News
IR
Swedish
Corporate Information
Other Corporate Information
Apr 19, 2021, 14:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 31, 2021, 14:05
News
IR
English
Regulatory
MAR
Corporate Information
Sales
Order
Mar 31, 2021, 14:05
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Mar 15, 2021, 09:55
News
PR
Swedish
Mar 11, 2021, 12:05
News
IR
Swedish
Corporate Information
Other Corporate Information
Mar 11, 2021, 12:05
News
IR
English
Corporate Information
Other Corporate Information
Feb 18, 2021, 12:50
News
IR
English
Corporate Information
Other Corporate Information
Feb 17, 2021, 13:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 17, 2021, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 10, 2021, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 10, 2021, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 04, 2021, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 04, 2021, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Feb 03, 2021, 08:14
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Feb 02, 2021, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se